|
| Friday, 22 June 2018, 10:00 HKT/SGT | |
| |  | |
Source: Autolus | |
|
|
|
LONDON, June 22, 2018 - (ACN Newswire) - Autolus Therapeutics plc ("Autolus"), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares ("ADSs") representing 8,823,530 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of approximately $150.0 million. All ADSs sold in the offering were offered by Autolus. The ADSs are expected to begin trading on The Nasdaq Global Select Market on June 22, 2018 under the ticker symbol "AUTL." In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 26, 2018, subject to customary closing conditions.
Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.
The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from either of the joint book-running managers for the offering, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at +1 866 471 2526 or by email at prospectusgroup-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by telephone at + 1 877 821 7388. For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant EU member state) and will not have been reviewed by any competent authority in any EU member state.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Investor Contact:
S.A. Noonan Communications, LLC
Susan A Noonan
+1 212 966 3650
susan@sanoonan.com
Media Contact:
JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours.
Forward-Looking Statements
This press release contains certain forward-looking statements, including statements with regard to Autolus' expectations regarding the commencement of trading of ADSs on The Nasdaq Global Select Market and the completion of the proposed securities offering. Words such as "anticipates," "believes," "expects," "intends," "projects," "anticipates," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Autolus, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Autolus' filings with the SEC. Autolus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Topic: Press release summary
Source: Autolus
Sectors: Science & Research, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
